Studies on antitumor activity, antimicrobial activity and toxicity of phleomycin.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use* / Q000633:toxicity / Q000652:urine; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001412:Bacillus subtilis / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D046508:Culture Techniques; D004285:Dogs; D004798:Enzymes / Q000494:pharmacology* / Q000633:toxicity; D004926:Escherichia coli / Q000187:drug effects; D006168:Guinea Pigs; D006367:HeLa Cells; D007674:Kidney Diseases / Q000139:chemically induced; D051379:Mice; D009161:Mycobacterium / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D012510:Sarcoma 180 / Q000188:drug therapy*; D012517:Sarcoma, Yoshida / Q000188:drug therapy*; D013210:Staphylococcus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D004798:Enzymes